Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment

ConclusionHCV treatment in a large community-based cohort demonstrated sustained improvements in AST, ALT, PLT, and FIB-4. Rebound increases in AST, ALT, and FIB-4 observed in Hispanics and those with BMI>30 kg/m2 may reflect persisting nonalcoholic fatty liver disease.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research

Related Links:

ConclusionHCV treatment in a large community-based cohort demonstrated sustained improvements in AST, ALT, PLT, and FIB-4. Rebound increases in AST, ALT, and FIB-4 observed in Hispanics and those with BMI>30 kg/m2 may reflect persisting nonalcoholic fatty liver disease.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
Publication date: Available online 21 December 2018Source: Journal of Advanced ResearchAuthor(s): Undurti N. DasAbstractIt has been suggested that hepatitis B virus (HBV)- and hepatitis C virus (HCV)-induced hepatic damage and cirrhosis and associated hypoalbuminemia, non-alcoholic fatty liver disease (NAFLD), and alcoholic fatty liver disease (AFLD) are due to an imbalance between pro-inflammatory and anti-inflammatory bioactive lipids. Increased tumour necrosis factor (TNF)-α production induced by HBV and HCV leads to a polyunsaturated fatty acid (PUFA) deficiency and hypoalbuminemia. Albumin mobilizes PUFAs from t...
Source: Journal of Advanced Research - Category: Research Source Type: research
Publication date: Available online 21 December 2018Source: Journal of Advanced ResearchAuthor(s): Undurti N. DasAbstractIt has been suggested that hepatitis B virus (HBV)- and hepatitis C virus (HCV)-induced hepatic damage and cirrhosis and associated hypoalbuminemia, non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD) are due to an imbalance between pro-inflammatory and anti-inflammatory bioactive lipids. Increased tumour necrosis factor (TNF)-α production induced by HBV and HCV leads to a polyunsaturated fatty acid (PUFA) deficiency and hypoalbuminemia. Albumin mobilizes PUFAs from th...
Source: Journal of Advanced Research - Category: Research Source Type: research
Abstract Chronic infection with the hepatitis C virus induces liver fibrosis, but it is unknown why some patients progress to advanced fibrosis while others remain with mild disease. Recently, an inverse association between serum levels of dehydroepiandrosterone sulphate (DHEA‐S) and liver fibrosis in patients with nonalcoholic fatty liver disease was described and it was postulated that dehydroepiandrosterone (DHEA) has anti‐fibrotic effects. Our aim was to compare serum DHEA‐S levels with liver fibrosis in hepatitis C patients. We collected serum samples from hepatitis C patients at the same day underwent a liver b...
Source: Journal of Viral Hepatitis - Category: Infectious Diseases Authors: Tags: Original Paper Source Type: research
ConclusionsEighty-five percent of the patients with non-B non-C HCC had at least one risk factor for NAFLD. None of the study patients had occult hepatitis B infection. NAFLD is emerging as the major etiological contributing factor for non-B non-C HCC in India.
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
Conclusion Elevated BMI was an independent risk factor associated with possible LC across the three different etiologies of CLD. As such, weight loss may be beneficial in these patients.
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. J Formos Med Assoc. 2017 Sep 22;: Authors: Yen YH, Chang KC, Tsai MC, Tseng PL, Lin MT, Wu CK, Lin JT, Hu TH, Wang JH, Chen CH Abstract BACKGROUND/PURPOSE: Metabolic risk factors are associated with liver fibrosis. Whether or not metabolic risk factors affect the severity of liver fibrosis in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC), or risk factors associated with non-alcoholic fatty liver disease (NAFLD) remains unclear. We aimed...
Source: J Formos Med Assoc - Category: General Medicine Authors: Tags: J Formos Med Assoc Source Type: research
Abstract Until the end of the 90's of the last century, rather little attention was paid to the issue of the non-alcoholic fatty liver disease (NAFLD), perhaps due to the fact that the newly discovered hepatitis C virus did attract a paramount interest of hepatologists and researchers. On the other side, fatty liver was considered a relatively uncommon cause of liver damage, occurring almost exclusively in obese females, often associated with non-insulin dependent diabetes mellitus (NIDDM), and with a relatively benign prognosis. Due to the complexity of international available guidelines, we decide to approach th...
Source: European Journal of Internal Medicine - Category: Internal Medicine Authors: Tags: Eur J Intern Med Source Type: research
CONCLUSIONS: Due to the very low quality evidence, we are very uncertain about the effectiveness of pharmacological treatments for people with NAFLD including those with steatohepatitis. Further well-designed randomised clinical trials with sufficiently large sample sizes are necessary. PMID: 28358980 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Tags: Cochrane Database Syst Rev Source Type: research
Abstract Gastrointestinal disorders are common complications of diabetes mellitus and include gastroparesis, nonalcoholic fatty liver disease, gastroesophageal reflux disease, and chronic diarrhea. Symptoms of gastroparesis include early satiety, postprandial fullness, nausea, vomiting of undigested food, bloating, and abdominal pain. Gastroparesis is diagnosed based on clinical symptoms and a delay in gastric emptying in the absence of mechanical obstruction. Gastric emptying scintigraphy is the preferred diagnostic test. Treatment involves glucose control, dietary changes, and prokinetic medications when needed....
Source: American Family Physician - Category: Primary Care Authors: Tags: Am Fam Physician Source Type: research
More News: Antiviral Therapy | Diabetes | Diabetes Mellitus | Endocrinology | Fatty Liver Disease (FLD) | Gastroenterology | Hepatitis | Hepatitis C | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Students | Universities & Medical Training | Urology & Nephrology